Characteristics of lipid metabolism disorders in patients with coronavirus infection-COVID-19 with chronic hepatitis C
https://doi.org/10.20340/vmi-rvz.2023.5.CLIN.11
Abstract
The aim of the study was to assess individual indicators of lipid metabolism in patients with novel coronavirus infection with chronic hepatitis C (CHC) depending on the severity of COVID-19 and liver fibrosis stage.
Object and methods. A comparative analysis of the results of laboratory examination of patients of the following groups was carried out: group 1 (n = 147) – patients with COVID-19 and CHC, group 2 (n = 81) – patients with COVID-19, group 3 control (n = 94) patients with CHC without COVID-19. In turn, the patients of the first two groups were divided into subgroups according to the severity of the COVID-19: with moderate (A) and severe course (B). According to the liver fibrosis stage, patients with COVID-19 with CHC were divided into 3 subgroups: F1 (mild fibrosis), F2 (moderate fibrosis), F3 (severe fibrosis). In blood serum, lipid profile parameters (total cholesterol (TC), high-density lipoprotein cholesterol (CHDL), low-density lipoprotein cholesterol (CLDL), triglycerides (TG), apolipoprotein A1 (Apo A1), apolipoprotein B (Apo B)) were evaluated. All parameters were assessed in the acute period, according to the severity of COVID-19 and the liver fibrosis stage.
Results. In 100% of patients with COVID-19 and CHC, a decrease in Apo A1 and an increase in Apo B, the ratio of Apo B/Apo A1 were detected, regardless the severity of disease. In patients with severe COVID-19 with CHC, changes in the lipid spectrum were recorded: an increase in TG, Apo AI, Apo B, Apo B/Apo A1 ratio, and a decrease in CHDL, CLDL, Apo A1. In patients with COVID19 and severe liver fibrosis (CHC), a decrease in LDLC, Apo A1 and increase in CLDL, Apo B, ratio Apo B/Apo A1 was observed.
About the Authors
E. I. Temnik
Samara State Medical University
Russian Federation
Russian Federation
89 Chapaevskaya str., Samara, 443099
D. Y. Konstantinov
Samara State Medical University
Russian Federation
Russian Federation
89 Chapaevskaya str., Samara, 443099
L. L. Popova
Samara State Medical University
Russian Federation
Russian Federation
89 Chapaevskaya str., Samara, 443099
References
1. 1 Cucinotta D., Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020;91:157–160. https://doi.org/10.23750/abm.v91i1.9397
2. 2 Fan Y., Li X., Zhang L., Wan S., Zhou F. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther. 2022;7:141. https://doi.org/10.1038/s41392-022-00997-x
3. 3 WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/
4. 4 Li Y., Zhang Y., Lu R., Dai M., Shen M., Zhang J. et al. Lipid metabolism changes in patients with severe COVID-19. Clin Chim Acta. 2021;517:66–73. https://doi.org/10.1016/j.cca.2021.02.011
5. 5 Sorokin A.V., Karathanasis S.K., Yang Z-H., Freeman L., Kotani K., Remaley A.T. COVID-19-associated dyslipidemia: implications for mechanism of impaired resolution and novel therapeutic approaches. FASEB J. 2020;34(8):9843–53. https://doi.org/10.1096/fj.202001451
6. 6 Xingzhong H., Dong C., Lianpeng W., Guiqing H., Wei Y. Low serum cholesterol level among patients with COVID-19 infection in Wenzhou, China. Lancet. 2020. http://dx.doi.org/10.2139/ssrn.3544826
7. 7 Fan J., Wang H., Ye G. et al. Letter to the Editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. Metabolism. 2020;107:154243.
8. 8 Liou J.W., Mani H., Yen J.H. Viral Hepatitis, Cholesterol Metabolism, and Cholesterol-Lowering Natural Compounds. Int J Mol Sci. 2022 Mar 31;23(7):3897. https://doi.org/10.3390/ijms23073897. PMID: 35409259; PMCID: PMC8999150
9. 9 Temporary guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)" Version 15 (02/22/2022) (In Russ).
10. 10 Clinical recommendations "Chronic viral hepatitis C" Ministry of Health of the Russian Federation. Year of approval: 2021 (In Russ).
11. 11 Arutyunov G.P. et al. Analysis of lipid spectrum parameters in hospitalized patients with COVID-19 depending on the outcome of the acute period of infection according to the international registry "Analysis of the dynamics of comorbid diseases in patients who have been infected with SARS-CoV-2". Russian Journal of Cardiology. 2022;27(9):5042. https://doi.org/10.15829/1560-4071-2022-5042 (In Russ).
12. 12 Fleck-Derderian S., McClellan W., Wojcicki J.M. The association between cytomegalovirus infection, obesity, and metabolic syndrome in U.S. adult females. Obesity (Silver Spring). 2017;25:626–633.
13. 13 Biswas H.H., Gordon A., Nu˜nez A., Perez M.A., Balmaseda A., Harris E. Lower Low-Density Lipoprotein Cholesterol Concentrations Are Associated with Severe Dengue Outcome. PLoS Negl. Trop. Dis. 2015;9:e3904.
14. 14 Wan J., Sun W., Li X. et al. Inflammation inhibitors were remarkably up-regulated in plasma of severe acute respiratory syndrome patients at progressive phase. Proteomics. 2006;6:2886–2894.
15. 15 Vercauteren K., Mesalam A.A., Leroux-Roels G., Meuleman P. Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization. World J Gastroenterol. 2014;20(43):15975–15991. PMID: 25473151, https://doi.org/10.3748/wjg.v20.i43.15975
16. 16 Sylvia Drazilova, Jakub Gazda, Martin Janicko, Peter Jarcuska, "Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy". Canadian Journal of Gastroenterology and Hepatology. 2018;2018:11. https://doi.org/10.1155/2018/6150861
17. 17 Yi Li, Yan Zhang, Rongli Lu, Minhui Dai, Minxue Shen, Jianchu Zhang et al. Lipid metabolism changes in patients with severe COVID-19. Clinica Chimica Acta. 2021;517:66-73. https://doi.org/10.1016/j.cca.2021.02.011
18. 18 Chemello K., Chan D.C., Lambert G., Watts G.F. Recent advances in demystifying the metabolism of lipoprotein(a). Atherosclerosis. 2022 May;349:82–91. https://doi.org/10.1016/j.atherosclerosis.2022.04.002; PMID: 35606080
Review
For citations:
Temnik E.I., Konstantinov D.Y., Popova L.L. Characteristics of lipid metabolism disorders in patients with coronavirus infection-COVID-19 with chronic hepatitis C. Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH). 2023;13(5):109-115. (In Russ.) https://doi.org/10.20340/vmi-rvz.2023.5.CLIN.11
Views:
229
Email this article 